Topics

Pharmaceutical Industry
Horizon Pharma buying Hyperion for about $1.1 billion

Irish firm Horizon Pharma is buying Hyperion Therapeutics for about $1.1 billion, gaining two treatments for genetic disorders. Dublin-based Horizon Pharma said Monday that it would pay $46 a share for the Brisbane, Calif., company, marking a 5.6% premium to Hyperion's closing stock price Friday, before the deal was announced. The move adds the drugs Raviciti and Buphenyl to Horizon's offerings. Both drugs are aimed at treating inherited disorders called urea cycle disorders that affect about 2,100 people in the U.S. The genetic condition affects how the body removes nitrogen from the blood. Nitrogen buildup can be toxic. Combined, the drugs had sales of $113.6 million in 2014....

Loading